Case Control Study
Copyright ©The Author(s) 2016.
World J Clin Pediatr. Aug 8, 2016; 5(3): 293-300
Published online Aug 8, 2016. doi: 10.5409/wjcp.v5.i3.293
Table 1 Descriptive characteristics at baseline and following the intervention by group
Resistance training group (n = 19)
Control group (n = 19)
Time effect (P value)Group effect (P value)Interaction (P value)
BaselineAfterBaselineAfter
Age, yr12.3 ± 0.4212.5 ± 0.4212.1 ± 0.3012.3 ± 0.30< 0.0010.1001.000
Height, cm151.4 ± 5.8153.4 ± 5.5151.0 ± 8.6152.7 ± 8.8< 0.0010.8000.300
Mass, kg42.8 ± 6.744.3 ± 7.340.5 ± 7.141.9 ± 7.3< 0.0010.3000.800
Body mass index, kg/m218.6 ± 2.418.8 ± 2.517.7 ± 2.317.9 ± 2.10.0480.2000.700
Body fat, %19.0 ± 6.119.0 ± 6.116.3 ± 3.716.3 ± 3.71.0000.1000.900
Fat free mass, %34.9 ± 4.536.1 ± 4.933.9 ± 5.935.0 ± 6.1< 0.0010.9000.600
SBP, mmHg110 ± 9107 ± 11108 ± 11107 ± 90.1310.7800.461
DBP, mmHg68 ± 667 ± 867 ± 867 ± 70.6520.7510.557
TC, mmol/L3.9 ± 0.63.7 ± 0.64.4 ± 0.54.2 ± 0.70.0250.0250.814
HDL-C, mmol/L1.5 ± 0.21.5 ± 0.31.7 ± 0.41.8 ± 0.50.2200.0470.278
LDL-C, mmol/L2.0 ± 0.61.8 ± 0.52.3 ± 0.52.0 ± 0.5< 0.0010.1990.850
TG, mmol/L1.0 ± 0.41.0 ± 0.40.9 ± 0.41.0 ± 0.40.5540.7560.848
Glucose, mmol/L5.1 ± 0.35.0 ± 0.34.9 ± 0.34.9 ± 0.30.2690.0940.315
log insulin, pmol/L4.4 ± 0.54.1 ± 0.34.0 ± 0.53.9 ± 0.50.0270.0990.169
hsCRP, mg/L0.31 ± 0.450.25 ± 0.350.19 ± 0.180.65 ± 2.30.4860.6380.344
Peak VO2, mL/min1741 ± 3221870 ± 4461776 ± 4661963 ± 5400.0030.7000.500
Peak VO2, mL/kg per minute40.5 ± 7.141.8 ± 8.043.1 ± 8.845.6 ± 7.90.0810.3000.600